US FDA clears first blood test to detect Alzheimer's disease
(Reuters) -The U.S. Food and Drug Administration said on Friday it has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, making it the first of its kind to detect the condition.
Blood testing is initially likely to be used to rule out Alzheimer's, with positive results signaling the need for more advanced diagnostics.
Alzheimer's, which gradually destroys memory and thinking skills, is characterized by changes in the brain including buildup of amyloid beta plaques and tau tangles that result in loss of neurons responsible for transmitting information.
Fujirebio's diagnostic device, will be used for early detection of amyloid plaques associated with the disease.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
5 hours ago
- Business Insider
U.S. aid cuts leave $11 million in birth control supplies for Sub-Saharan Africa stranded
Millions of contraceptives intended to support women across Africa are reportedly sitting idle in warehouses and are at risk of being destroyed due to delays and funding cuts from the United States government. Millions of contraceptives intended for Africa are at risk of expiration due to U.S. government delays and funding cuts. The supplies, valued at $11 million, include various contraceptive tools meant for low-income countries. The delayed distribution may lead to increased health risks and strain on the healthcare systems in Africa. A former US official and aid worker revealed that the contraceptives, valued at around $11 million, include condoms, birth control pills, implants, and intrauterine devices (IUDs), which were originally intended to help women in low-income countries, particularly in sub-Saharan Africa, avoid unplanned pregnancies and protect themselves from sexually transmitted infections like HIV. However, the supplies are now stuck in storage facilities in Belgium and Dubai. According to sources at Reuters, the U.S. The Agency for International Development (USAID) has decided not to pay for their delivery and is no longer donating them as part of foreign aid programs. This delay stems from policy changes implemented by the former U.S. President Donald Trump, who reduced foreign assistance under his 'America First' approach: USAID gives update A recent internal memo from USAID, dated April, highlighted the urgent need to transfer the stock to prevent waste and minimize further costs. Despite this warning, a concrete plan has yet to be announced. With each passing month, the contraceptives edge closer to expiration. A senior U.S. State Department officials further confirmed that the contraceptives remain in storage, but no final decision has been made regarding their fate. The situation, according to the US official, is both frustrating and urgent for many health workers and aid groups. Another former USAID official said the stalled shipment represents nearly 20% of all contraceptives the U.S. usually donates each year, adding that if no solution is found soon, the entire stock could be destroyed, at a cost of hundreds of thousands of dollars. 'These supplies were meant to help women who have little or no access to family planning—girls fleeing conflict, mothers in refugee camps, and young women at risk of early pregnancy, ' one source said. ' The condoms in the shipment were also meant to help prevent the spread of HIV, which continues to impact millions across the region.' It added. Karen Hong, head of supply chain at the United Nations Population Fund (UNFPA), said her team is already working on an alternative plan. ' We cannot dwell on an issue for too long; when urgency and clarity don't align, we have to move on,' she said.
Yahoo
11 hours ago
- Yahoo
FDA clears first blood test to help diagnose Alzheimer's disease
The test is for those aged 55 and older who are already exhibiting signs and symptoms of Alzheimer's disease.
San Francisco Chronicle
12 hours ago
- San Francisco Chronicle
New Alzheimer's blood tests make diagnosis easier — but they're not right for everyone
The number of Americans with Alzheimer's disease, the most common cause of dementia in the U.S., is projected to rise significantly in the coming decades. The devastating disease has no cure, but the past several years have brought promising developments in new drug therapies and blood tests that help doctors treat and diagnose the disease. Here's what to know about the blood tests that diagnose Alzheimer's, one of which got full FDA approval in May. How they work Several commercially available blood tests have become available the past few years, most recently from biotech company Fujirebio Diagnostics, which got full approval from the FDA last month. Each test measures slightly different things, but overall they look for abnormal levels of certain proteins — amyloid and tau — in the blood. The accumulation of amyloid and tau proteins in the brain, often called plaques, are hallmark signs of Alzheimer's. If someone has tau plaques in the brain, for instance, some of that will leak out of the brain into the blood, resulting in a blood test result showing higher than normal levels of tau. In patients with symptoms of cognitive impairment, the tests predict an Alzheimer's diagnosis with about 90% accuracy. Why they're important The blood tests are a notable development because they are less expensive and less invasive than other types of testing that doctors have long used to diagnose patients with Alzheimer's. One is a PET scan, which involves injecting a patient with a radioactive tracer that binds to amyloid or tau in the brain so the presence of the proteins can be seen in a scan. It can cost several thousand dollars, compared to several hundred dollars for a blood test. The other is a spinal tap, which is painful or uncomfortable for many people. This method measures different forms of amyloid and tau in the spinal fluid. 'Up until these blood tests came out, a physician was stuck doing a PET scan or spinal tap, so not great options,' said Dr. Frank Longo, a professor of neurology at Stanford Medicine. 'The big breakthrough is finding something to measure in the blood that's about 90% accurate of what's going on in the brain, about as accurate as spinal fluid or a PET scan.' Doctors use the blood test as part of a broader medical evaluation that also includes a patient history, neurological exam and other testing. The blood test can help rule out Alzheimer's as the cause of a patient's cognitive impairment and potentially avoid unnecessary further testing. If someone's blood test comes back normal, for example, they may not have to undergo the PET scan or spinal tap, and their doctor can look into other potential causes of the cognitive impairment. 'That's the biggest practical thing it's doing now,' Longo said. It's important to distinguish Alzheimer's from other types of dementia because there are Alzheimer's treatments that have come out the last few years that help slow the progression of Alzheimer's. But patients must be in relatively early stages of the disease, with mild impairment or mild dementia, to be eligible. Some of the therapies have significant side effects, so patients would not want to start them unless they knew it was Alzheimer's, and not something else, causing the dementia. They're not for everyone The tests are approved only for people who already have symptoms of cognitive impairment and are of a certain age — 55 and over or 60 and over, depending on the test. They are not approved for healthy adults with normal cognition who want to diagnose or rule out Alzheimer's, or who are simply curious if they are at risk for developing Alzheimer's. They must be ordered by a doctor. They're becoming more common, but may not be covered by insurance Some of the blood tests have been available for a year or two, Longo said, but they were under an earlier and more limited type of FDA approval, not the full approval that the agency granted last month to the Fujirebio test. So they are poised to become more common. 'A year ago, most of my colleagues and I were not ordering these,' Longo said. 'I'd say less than 5% or 10% of the time we were ordering these. Now people are starting to order them in symptomatic patients. It's not rare now. They're starting to be recognized more.' Some primary care doctors are starting to order the tests as well, said Dr. Armen Moughamian, medical director of Sutter Health's Ray Dolby Brain Center at CPMC in San Francisco. The center treats patients with memory disorders. 'It's definitely a minority, but I've been seeing it done,' he said. As with many new medical tests, insurers may not cover them yet, but that usually evolves over time. Full FDA approval may help make the case for the tests to be covered, Longo said. 'There is some uncertainty and lack of clarity about whether insurance and Medicare pay,' Moughamian said. 'That creates some hesitancy for providers to order it.' They may one day be used to screen and diagnose healthy people earlier In people with Alzheimer's, amyloid plaques begin to form in the brain as many as 20 years before they show symptoms. Right now, newer therapies for Alzheimer's — like lecanemab and donanemab, which slow the progression of the disease — are approved only for people with symptoms. Those symptoms are mild cognitive impairment or mild dementia, the early stages of symptomatic Alzheimer's. This means people who have not yet developed symptoms, but who have amyloid plaques in the brain, cannot get these treatments. So if a blood test could be used in pre-symptomatic people, it could mean better screening and earlier diagnosis to larger groups of people. 'What we want to push for is earlier diagnosis because new therapies are available when we catch people in earlier stages,' Moughamian said. Moughamian is leading two clinical trials that examine whether drugs that remove amyloid in the brain, donanemab and another drug remternetug, can work in people who have amyloid plaques but have not yet developed symptoms. They are using an Alzheimer's blood test to see whether patients are eligible for the trial.
